Unlike FDA-approved medicines, compounded GLP-1 drugs and products promoted as alternatives to the FDA-approved versions such as oral supplements and patches do not go through the FDAs rigorous review process to ensure safety, effectiveness, and quality
Why Weight Loss Peptides Matter in Modern Obesity Medicine The clinical approach to weight management requires targeted interventions that address the biological drivers of obesity
Data availability All data generated or analyzed during this study are included in this published article
It may not be suitable for individuals with a history of pancreatitis, severe gastrointestinal disease, certain thyroid cancers, or those who are pregnant or breastfeeding
WEGOVY (Semaglutide) Prescribing Information (US Food and Drug Administration, 2021)
DPP-4 degrades GLP-1 (7-36) into the non insulinotropic GLP-1 (9-36) (some studies suggest it may have weak insulinotropic activity)